Enanta Pharma (NASDAQ: ENTA) reported Q1 EPS of ($0.26), $0.08 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $11.9 million versus the consensus estimate of $11.94 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.